OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe
May 5, 2020
OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.
Scandinavian Sales Agreement Expands Creso Pharma’s European Footprint
Mar 4, 2020
Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed a commercial term sheet agreement with Farmagon, Oslo, Norway to enter the Scandinavia market with Creso products.
Creso on a Roll: New Hemp Plant Product for Equines and Large Animals Set for Release
Feb 11, 2020
Creso Pharma (ASX:CPH) today announced the successful development of anibidiol®EQUI, a flavoured micromilled hemp plant product for equines and large animals.
CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs
Jan 21, 2020
Momentum has been building over the last couple of months as CresoPharma (ASX:CPH) outlined its strategy for generating substantial growth in 2020.
ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations
Dec 19, 2019
One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).
Can New Cannabis Products Launch Creso Pharma Higher in 2020?
Dec 3, 2019
Through partnerships with leading global companies, Creso Pharma (ASX:CPH) has been able to, and will continue to accelerate the development and distribution of its products worldwide.
ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await
Nov 7, 2019
One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.
GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer
Oct 2, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).
One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market
Aug 14, 2019
MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.
IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking
Jul 25, 2019
Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.